UroGen Pharma (URGN) has crossed above its average 12-month analyst target of $36.88, trading at $37.94/share. The move suggests the stock is outperforming the Street’s baseline target, though the article provides no new fundamentals or guidance change. Net impact is likely limited absent additional analyst revisions.
UroGen Pharma (URGN) has crossed above its average 12-month analyst target of $36.88, trading at $37.94/share. The move suggests the stock is outperforming the Street’s baseline target, though the article provides no new fundamentals or guidance change. Net impact is likely limited absent additional analyst revisions.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.08
Ticker Sentiment
